Morgan Stanley raised the firm’s price target on Donaldson (DCI) to $69 from $65 and keeps an Underweight rating on the shares. The firm updated estimates and is rolling forward its valuation to FY26 and increasing share repurchase expectations, but remains Underweight following fiscal Q3 reporting as it continues to see risk to the Life Sciences growth strategy, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCI:
- Hold Rating on Donaldson Company Amid Bioprocessing Challenges and Market Uncertainties
- Donaldson price target raised to $78 from $76 at Baird
- Donaldson’s Business at Risk: How International Tariffs Could Impact Operations and Competitiveness
- Morning Movers: Signet Jewelers and Dollar General surge following Q1 results
- Donaldson Company Appoints New COO Amidst Strong Q3 Results